Pediatric standard-risk AML with fully matched sibling donors: to transplant in first CR or not?
Allogeneic hematopoietic SCT (HSCT) for children with standard-risk AML in first CR (CR1) is controversial. We reviewed 32 consecutive children with standard-risk AML who received matched sibling donor HSCT in CR1 from 1995 to 2004. With a median follow-up of 76 months (range: 36-114), 3 year EFS was 0.74 (95% confidence interval (CI): 0.57-0.88) and the overall survival was 0.81 (95% CI: 0.66-0.93). Only one patient died as a result of TRM. Larger studies, such as the MRC-UK 10 and 12, reported 60-62% EFS. Outcome of children with standard-risk AML transplanted from a matched sibling donor in CR1 is very encouraging with minimal toxicity.